Ticagrelor
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Ticagrelor structure.svg | |
| Ticagrelor
| |
| Systematic (IUPAC) name | |
| (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol | |
| Identifiers | |
| CAS number | |
| ATC code | none |
| PubChem | |
| Chemical data | |
| Formula | C23H28F2N6O4S |
| Mol. mass | 522.567 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | oral |
|
WikiDoc Resources for Ticagrelor | |
|
Articles | |
|---|---|
|
Most recent articles on Ticagrelor | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Ticagrelor at Clinical Trials.gov Clinical Trials on Ticagrelor at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Ticagrelor
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Ticagrelor Discussion groups on Ticagrelor Patient Handouts on Ticagrelor Directions to Hospitals Treating Ticagrelor Risk calculators and risk factors for Ticagrelor
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Ticagrelor | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Ticagrelor (AZD6140) is a platelet aggregation inhibitor produced by AstraZeneca. As of February 2008, a clinical trial (PLATO: Platelet inhibition and patient outcomes) is comparing a combination of ticagrelor plus aspirin to clopidogrel plus aspirin for the prevention of thromboembolism.
Method of action
Like clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.[1][2]
PLATO trial
This trial, recently published in New England Journal of Medicine, has confirmed the superiority of ticagrelor over clopidogel in patients with acute coronary syndromes.[3]
References
- ↑ H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140" (in German). Österreichische Apothekerzeitung (3/2008): 135.
- ↑ Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.
- ↑ Wallentin, Lars (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM.
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
